Subsequent anti-VEGF therapy after first-line anti-EGFR therapy improved overall survival of patients with metastatic colorectal cancer.

about

Subsequent anti-VEGF therapy after first-line anti-EGFR therapy improved overall survival of patients with metastatic colorectal cancer.

Item

http://www.wikidata.org/entity/Q48512300

description

2018 nî lūn-bûn

@nan

2018年の論文

@ja

2018年学术文章

@wuu

2018年学术文章

@zh-cn

2018年学术文章

@zh-hans

2018年学术文章

@zh-my

2018年学术文章

@zh-sg

2018年學術文章

@yue

2018年學術文章

@zh

2018年學術文章

@zh-hant

name

Subsequent anti-VEGF therapy a ...... metastatic colorectal cancer.

@en

Subsequent anti-VEGF therapy a ...... metastatic colorectal cancer.

@nl

type

Item

label

Subsequent anti-VEGF therapy a ...... metastatic colorectal cancer.

@en

Subsequent anti-VEGF therapy a ...... metastatic colorectal cancer.

@nl

prefLabel

Subsequent anti-VEGF therapy a ...... metastatic colorectal cancer.

@en

Subsequent anti-VEGF therapy a ...... metastatic colorectal cancer.

@nl

P1476

Subsequent anti-VEGF therapy a ...... metastatic colorectal cancer.

@en

P2093

Jing Sun

http://www.w3.org/2001/XMLSchema#string

Ping Li

http://www.w3.org/2001/XMLSchema#string

Tianzhu Qiu

http://www.w3.org/2001/XMLSchema#string

Wensen Chen

http://www.w3.org/2001/XMLSchema#string

Xiaofeng Chen

http://www.w3.org/2001/XMLSchema#string

Yanhong Gu

http://www.w3.org/2001/XMLSchema#string

P2860

KRAS mutation status is predictive of response to cetuximab therapy in colorectal cancer.

Effects of KRAS, BRAF, NRAS, and PIK3CA mutations on the efficacy of cetuximab plus chemotherapy in chemotherapy-refractory metastatic colorectal cancer: a retrospective consortium analysis.

Cetuximab and chemotherapy as initial treatment for metastatic colorectal cancer

Chemotherapy, bevacizumab, and cetuximab in metastatic colorectal cancer

Cetuximab plus irinotecan, fluorouracil, and leucovorin as first-line treatment for metastatic colorectal cancer: updated analysis of overall survival according to tumor KRAS and BRAF mutation status

Addition of cetuximab to oxaliplatin-based first-line combination chemotherapy for treatment of advanced colorectal cancer: results of the randomised phase 3 MRC COIN trial.

Review of epidermal growth factor receptor biology.

PEAK: a randomized, multicenter phase II study of panitumumab plus modified fluorouracil, leucovorin, and oxaliplatin (mFOLFOX6) or bevacizumab plus mFOLFOX6 in patients with previously untreated, unresectable, wild-type KRAS exon 2 metastatic color

FOLFIRI plus cetuximab versus FOLFIRI plus bevacizumab as first-line treatment for patients with metastatic colorectal cancer (FIRE-3): a randomised, open-label, phase 3 trial.

Does bevacizumab impact anti-EGFR therapy efficacy in metastatic colorectal cancer?

P304

465-471

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.2147/OTT.S149110

http://www.w3.org/2001/XMLSchema#string

P407

English

P478

http://www.w3.org/2001/XMLSchema#string

P577

2018-01-22T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

29403291

http://www.w3.org/2001/XMLSchema#string

P921

colorectal cancer

P932

5784580

http://www.w3.org/2001/XMLSchema#string